scholarly journals Abnormal mucus in cap polyposis

Gut ◽  
1998 ◽  
Vol 42 (1) ◽  
pp. 135-138 ◽  
Author(s):  
M P Buisine ◽  
J F Colombel ◽  
M Lecomte-Houcke ◽  
P Gower ◽  
J P Aubert ◽  
...  
Keyword(s):  
In Situ Hybridisation ◽  
Clinical Manifestations ◽  
Goblet Cells ◽  
Biopsy Specimens ◽  
Mucin Genes ◽  
Cap Polyposis ◽  
Abnormal Glycosylation ◽  
Histochemical Examination ◽  
Mrna In Situ Hybridisation

Background—Cap polyposis is a rare disease characterised by mucoid and bloody diarrhoea, with polyps covered by a cap of mucoid and fibrinopurulent exudate. The pathogenesis is not known.Aims—To pour some light on cap polyposis pathogenesis, by examining the mucus of patients and analysing the expression of five mucin genes, MUC2, MUC3,MUC4, MUC5AC, and MUC5B.Patient and methods—The study was performed on biopsy specimens taken from a patient with recurrent cap polyposis. Histochemical examination, electron microscopy, and mRNA in situ hybridisation were used.Results—The mucus of cap polyposis differed in three respects from that of normal adult colon: abnormal ultrastructure of the mucus in the goblet cells, predominance of non-sulphated mucins, abnormal expression of the MUC4, MUC3, andMUC5AC genes.Conclusions—Most of these abnormalities have been reported for other pathological situations, suggesting that the abnormalities observed in the mucus of this patient with cap polyposis are probably secondary phenomena rather than primary. However, the mucin abnormalities detected, which reflect deregulation of the expression of three apomucin genes, abnormal glycosylation, and abnormalities of the secretion process, are also probably involved in the clinical manifestations of cap polyposis.

SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients

2013 ◽  
Vol 66 (5) ◽  
pp. 409-414 ◽  
Author(s):  
Timothy Michael D'Alfonso ◽  
Yi-Fang Liu ◽  
Zhengming Chen ◽  
Ying-Bei Chen ◽  
Ashley Cimino-Mathews ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Core Biopsy ◽  
In Situ Hybridisation ◽  
Excisional Biopsy ◽  
Needle Core Biopsy ◽  
Breast Cancer Patients ◽  
Biopsy Specimens ◽  
Her 2

Accurate assessment of HER-2/neu gene status in breast cancer patients has important prognostic and therapeutic implications. Overexpression/gene amplification of HER-2 is associated with a more aggressive clinical course and eligibility for targeted therapy with trastuzumab. A variety of immunohistochemical (IHC) antibodies and in situ hybridisation (ISH) methods have been employed to assess HER-2 status. SP3 is a rabbit monoclonal antibody that has been shown to have a high level of agreement with other anti-HER-2 antibodies and ISH methods. We assessed HER-2 status by SP3 and HercepTest IHC stains and by fluorescence in situ hybridisation (FISH) on invasive breast carcinomas from paired needle core biopsy and excisional biopsy specimens from 100 patients. We compared the two antibodies with respect to concordance rates with FISH, concordance rates between samples of the same tumour, and sensitivity and specificity using FISH as the reference test. Concordance between SP3 and FISH in needle core biopsy and excisional biopsy specimens was 96% (95% CI 91.9% to 99.7%) (κ=0.89 (95% CI 0.73 to 1.00)) and 97% (95% CI 90.3% to 99.3%) (κ=0.84 (95% CI 0.66 to 1.00)), respectively. Sensitivity and specificity of SP3 for detecting HER-2 overexpression/gene amplification were 78.3% and 100%, respectively, in needle core biopsy and excisional biopsy specimens. Concordance between SP3 results assessed on the needle core biopsy and excisional biopsy was 89% (95% CI 81.2% to 94.4%) (κ=0.62 (95% CI 0.42 to 0.82)). Concordance between SP3 and HercepTest antibodies, after excluding 2+ cases, was 97.6% (95% CI 94.0% to 99.3%) (κ=0.88 (95% CI 0.77 to 1.00)). SP3 is a reliable alternative to HercepTest in evaluating HER-2 status in breast cancer patients. Like other anti-HER-2 antibodies, SP3 may serve as a diagnostic tool in breast pathology and has potential utility as an IHC biomarker in non-mammary malignancies.

scholarly journals Model system for optimising mRNA non-isotopic in situ hybridisation: riboprobe detection of lysozyme mRNA in archival gut biopsy specimens.

1991 ◽  
Vol 44 (10) ◽  
pp. 835-839 ◽  
Author(s):  
J C Martinez-Montero ◽  
C S Herrington ◽  
J Stickland ◽  
H Sawyer ◽  
M Evans ◽  
...  
Keyword(s):  
In Situ Hybridisation ◽  
Model System ◽  
Biopsy Specimens

Fluorescence in situ hybridisation analysis of bone marrow trephine biopsy specimens; an additional tool in the diagnostic armoury

2012 ◽  
Vol 66 (1) ◽  
pp. 54-57 ◽  
Author(s):  
Michael J Neat ◽  
Mufaddal T Moonim ◽  
Robert G Dunn ◽  
Helen Geoghegan ◽  
Nicola J Foot
Keyword(s):  
In Situ Hybridisation ◽  
Fish Analysis ◽  
Fluorescence In Situ Hybridisation ◽  
Trephine Biopsy ◽  
Additional Tool ◽  
Bone Marrow Trephine Biopsy ◽  
Biopsy Specimens ◽  
Wide Range ◽  
Formalin Fixed Paraffin Embedded

Fluorescence in situ hybridisation (FISH) analysis is now widely employed in the diagnosis and risk stratification of a wide range of malignant diseases. While this technique is used successfully with formalin-fixed paraffin-embedded (FFPE) sections from numerous tissue types, FISH analysis of FFPE tissue sections from trephine biopsy specimens has been less widely reported, possibly due to technical limitations relating to the decalcification protocols employed. During the last 4 years FISH analysis has been carried out successfully in 42 out of 55 (76%) consecutive trephine biopsy specimens received as part of the standard diagnostic service at our institution. Samples decalcified using EDTA-based protocols were analysed successfully in 31/31 cases (100%), whereas only 11/24 samples (46%) decalcified using formic acid-based protocols were successful. In our experience, FISH analysis of trephine biopsy specimens is a highly reproducible technique and a very useful adjunctive tool in the diagnostic armoury; however, its use in a standard diagnostic setting relies on the use of EDTA-based decalcification protocols.

T1738 Stem Cell Location Throughout the Human Gastrointestinal Tract as Defined by LGR5 mRNA in Situ Hybridisation

2010 ◽  
Vol 138 (5) ◽  
pp. S-568
Author(s):  
Stuart A. McDonald ◽  
Rosemary Jeffery ◽  
Adam Humphries ◽  
Simon Leedham ◽  
Trevor A. Graham ◽  
...  
Keyword(s):  
Stem Cell ◽  
Gastrointestinal Tract ◽  
In Situ Hybridisation ◽  
Human Gastrointestinal Tract ◽  
Mrna In Situ Hybridisation

scholarly journals Detection of human papillomavirus in matched cervical smears and biopsy specimens by non-isotopic in situ hybridisation.

1992 ◽  
Vol 45 (4) ◽  
pp. 308-313 ◽  
Author(s):  
G Troncone ◽  
C S Herrington ◽  
K Cooper ◽  
M L de Angelis ◽  
J O McGee
Keyword(s):  
Human Papillomavirus ◽  
In Situ Hybridisation ◽  
Cervical Smears ◽  
Biopsy Specimens

scholarly journals Critical evaluation ofKCNJ3gene product detection in human breast cancer: mRNA in situ hybridisation is superior to immunohistochemistry

2016 ◽  
Vol 69 (12) ◽  
pp. 1116-1121 ◽  
Author(s):  
Sarah Kammerer ◽  
Stephan Wenzel Jahn ◽  
Elke Winter ◽  
Sylvia Eidenhammer ◽  
Simin Rezania ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
In Situ Hybridisation ◽  
Critical Evaluation ◽  
Human Breast ◽  
Mrna In Situ Hybridisation

scholarly journals Developmental expression of mucin genes in the human gastrointestinal system

Gut ◽  
1998 ◽  
Vol 42 (2) ◽  
pp. 220-226 ◽  
Author(s):  
C J Reid ◽  
A Harris
Keyword(s):  
Gastrointestinal Tract ◽  
Age Of Onset ◽  
In Situ Hybridisation ◽  
Normal Function ◽  
Developmental Expression ◽  
Pancreatic Ducts ◽  
Mucin Gene ◽  
Mucin Genes ◽  
Human Fetal Tissues

Background and aims—Mucin glycoproteins play a key role in the normal function of the epithelium lining the gastrointestinal tract. The expression of mucin genes, MUC 3, 4, 5AC, 5B, 6, 7, and 8 in human fetal tissues was examined to establish the localisation and age of onset of expression of each mucin gene during human development.Methods—Mucin gene expression was assayed by mRNA in situ hybridisation.Results—Expression of MUC3 was detected in the small intestine and colon from 13 weeks gestation onwards and at low levels in the main pancreatic duct at 13 weeks only. MUC4 expression was seen at a low level in the colonic epithelium from 13 weeks of gestation but not elsewhere in the gastrointestinal tract. MUC5AC mRNA was detected in the colon at 17 weeks and at high levels in the stomach at 23 weeks. MUC6transcripts were evident in the pancreatic ducts from 13 weeks of gestation and at high levels in the stomach at 23 weeks.MUC5B, MUC7, and MUC8transcripts were not detected.Conclusions—Mucin genes are expressed from the early mid-trimester of gestation in the developing human fetal gastrointestinal tract.

Sign in / Sign up

Export Citation Format

Share Document